239 related articles for article (PubMed ID: 23570383)
1. Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.
Balachandran S; Adams GP
J Interferon Cytokine Res; 2013 Apr; 33(4):171-80. PubMed ID: 23570383
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.
Chen P; Nogusa S; Thapa RJ; Shaller C; Simmons H; Peri S; Adams GP; Balachandran S
PLoS One; 2013; 8(4):e61446. PubMed ID: 23613854
[TBL] [Abstract][Full Text] [Related]
3. NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.
Thapa RJ; Chen P; Cheung M; Nogusa S; Pei J; Peri S; Testa JR; Balachandran S
Mol Cancer Ther; 2013 Aug; 12(8):1568-78. PubMed ID: 23657944
[TBL] [Abstract][Full Text] [Related]
4. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
[TBL] [Abstract][Full Text] [Related]
5. Involvement of double-stranded RNA-activated protein kinase in the synergistic activation of nuclear factor-kappaB by tumor necrosis factor-alpha and gamma-interferon in preneuronal cells.
Cheshire JL; Williams BR; Baldwin AS
J Biol Chem; 1999 Feb; 274(8):4801-6. PubMed ID: 9988719
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation.
Cheshire JL; Baldwin AS
Mol Cell Biol; 1997 Nov; 17(11):6746-54. PubMed ID: 9343439
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
9. Effects of retinoic acid and interferon-gamma on expression of the retinoic acid receptor in mouse renal cell carcinoma.
Hara I; Taguchi I; Miyake H; Hara S; Gotoh A; Kamidono S
Int J Oncol; 2001 Nov; 19(5):959-62. PubMed ID: 11604994
[TBL] [Abstract][Full Text] [Related]
10. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.
Mizokami MM; Hu P; Khawli LA; Li J; Epstein AL
Hybrid Hybridomics; 2003 Aug; 22(4):197-207. PubMed ID: 14511565
[TBL] [Abstract][Full Text] [Related]
11. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts.
van Dijk J; Uemura H; Beniers AJ; Peelen WP; Zegveld ST; Fleuren GJ; Warnaar SO; Oosterwijk E
Int J Cancer; 1994 Jan; 56(2):262-8. PubMed ID: 8314310
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
[TBL] [Abstract][Full Text] [Related]
14. NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis.
Thapa RJ; Basagoudanavar SH; Nogusa S; Irrinki K; Mallilankaraman K; Slifker MJ; Beg AA; Madesh M; Balachandran S
Mol Cell Biol; 2011 Jul; 31(14):2934-46. PubMed ID: 21576359
[TBL] [Abstract][Full Text] [Related]
15. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C
Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924
[TBL] [Abstract][Full Text] [Related]
17. Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1.
Held TK; Weihua X; Yuan L; Kalvakolanu DV; Cross AS
Infect Immun; 1999 Jan; 67(1):206-12. PubMed ID: 9864217
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-10 inhibits interferon-gamma-induced intercellular adhesion molecule-1 gene transcription in human monocytes.
Song S; Ling-Hu H; Roebuck KA; Rabbi MF; Donnelly RP; Finnegan A
Blood; 1997 Jun; 89(12):4461-9. PubMed ID: 9192770
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha.
Aulitzky WE; Aulitzky WK; Frick J; Herold M; Gastl G; Tilg H; Berger M; Huber C
Immunobiology; 1990 Jun; 180(4-5):385-94. PubMed ID: 2118879
[TBL] [Abstract][Full Text] [Related]
20. Cytokine-stimulated GTP cyclohydrolase I expression in endothelial cells requires coordinated activation of nuclear factor-kappaB and Stat1/Stat3.
Huang A; Zhang YY; Chen K; Hatakeyama K; Keaney JF
Circ Res; 2005 Feb; 96(2):164-71. PubMed ID: 15604419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
